{"source_content":"行业研究证券研究报告行业重大事件点评报告1月血制品行业批签发数据点评--医药行业点评报告分析师：王雯执业证书编号：S1380516110001联系电话：010-88300898邮箱：wangwen@gkzq.com.cn医药生物与上证综指走势图数据来源：wind，国开证券研究部行业评级中性相关报告药品集采常态化制度化开展意见发布——行业重大事件点评报告2021年2月18日日前，2021年1月血制品批签发数据基本公布完毕。1月，我国血制品实现批签发701.7万瓶，同比下滑7.2%，环比下滑30.96%，其中人凝血因子(Ⅷ)、狂免、人凝血酶原复合物、静丙等重点品种批签发同比有较大下滑。1月，人血白蛋白批签发433.8万瓶，同比下滑1%。其中进口白蛋白批签发261.5万瓶（-14.9%），国产白蛋白批签发172.3万瓶（+33.7%），进口白蛋白占比60.27%，国产白蛋白占比39.73%。整体看，进口白蛋白的批签发量有所下滑，特别去年同期还存在春节放假因素，导致实际批签发工作日缩短。由于去年海外疫情的持续，进口白蛋白的供给偏紧有望在今年陆续传导给国内，可持续跟踪。若进口白蛋白持续供给紧张，国内白蛋白价格存有一定的上涨空间。静丙方面，1月份共批签发静丙104.8万瓶，同比下滑-13%。其中天坛生物批签发达到42.8万瓶，占比42%。特免方面，狂免、破免及乙免分别批签发40.8万瓶（-47%）、64.9万瓶（+70%）及24.5万瓶（+151%）。因子类产品方面，人凝血因子(Ⅷ)、纤原及人凝血酶原复合物分别批签发7.03万瓶（-79%）、10.2万瓶（42%）和4.76万瓶（-24%）。其中人凝血因子(Ⅷ)1月批签发大幅下降，仅绿十字中国、上海莱士及双林生物实现批签发。从上市公司看，天坛生物白蛋白、静丙、狂免、破免共4个产品实现批签发，其中白蛋白、静丙同比增速大幅提升，分别为143%和58%。华兰生物白蛋白、静丙、乙免、凝血酶原共4个品种实现批签发，静丙、乙免、凝血酶原增速提升较大，白蛋白增速有所下滑。双林生物白蛋白、静丙、狂免、破免以及人凝血因子(Ⅷ)共5个产品实现批签发，其中人凝血因子(Ⅷ)为去年6月底获批后首次批签发。博雅生物1月份仅批签发白蛋白、静丙、纤原3个品种。整体我们认为血制品行业在供需关系推动下，景气度有望持续改善，建议密切跟踪进口白蛋白批签发情况，建议逢低关注以天坛生物、华兰生物为代表的行业龙头。风险提示：疫情影响超预期；行业监管政策进一步收紧；医保政策压力；行业事件性负面冲击；上市公司业绩增长低于预期；国内外经济形势持续恶化风险；国内外市场整体系统性风险。行业重大事件点评报告请务必阅读正文之后的免责条款部分2of4日前，中国食品药品检定研究院及各地药品检验所已陆续将2021年1月我国血制品批签发数据披露完毕。2021年1月，我国血制品实现批签发701.7万瓶，同比下滑7.2%，环比下滑30.96%，其中人凝血因子(Ⅷ)、狂免、人凝血酶原复合物、静丙等重点品种批签发同比有较大下滑。分品种看，人血白蛋白1月份批签发433.8万瓶（统一折算为10g规格），同比下滑1%。其中进口白蛋白批签发261.5万瓶（-14.9%），国产白蛋白批签发172.3万瓶（+33.7%），进口白蛋白占比60.27%，国产白蛋白占比39.73%。整体看，进口白蛋白的批签发量有所下滑，特别去年同期还存在春节放假因素，导致实际批签发工作日缩短。由于去年海外疫情的持续，进口白蛋白的供给偏紧有望在今年陆续传导给国内，可持续跟踪。若进口白蛋白持续供给紧张，国内白蛋白价格存有一定的上涨空间。静丙方面，1月份共批签发静丙104.8万瓶（含冻干，统一折算为2.5g规格），同比下滑-13%。其中天坛生物批签发达到42.8万瓶，占比42%，同比增长58%。另外人免批签发10.9万瓶，同比减少59%。特免方面，狂免、破免及乙免分别批签发40.8万瓶（-47%）、64.9万瓶（+70%）及24.5万瓶（+151%）。因子类产品方面，人凝血因子(Ⅷ)、纤原及人凝血酶原复合物分别批签发7.03万瓶（-79%）、10.2万瓶（42%）和4.76万瓶（-24%）。其中人凝血因子(Ⅷ)1月批签发大幅下降，仅绿十字中国、上海莱士及双林生物实现批签发，其中双林生物是自去年6月底获批后首次批签发，数量约1589瓶。从上市公司看，天坛生物白蛋白、静丙、狂免、破免共4个产品实现批签发，其中白蛋白、静丙同比增速大幅提升，分别为143%和58%。华兰生物白蛋白、静丙、乙免、凝血酶原共4个品种实现批签发，静丙、乙免、凝血酶原增速提升较大，白蛋白增速有所下滑。双林生物白蛋白、静丙、狂免、破免以及人凝血因子(Ⅷ)共5个产品实现批签发，其中人凝血因子(Ⅷ)为去年获批后首次批签发。博雅生物1月份仅批签发白蛋白、静丙、纤原3个品种，白蛋白批签发量大幅增长，但静丙批签发量有所下滑。上海莱士1月批签发白蛋白、静丙、乙免、破免、人凝血因子(Ⅷ)和纤原6个品种，除纤原增长及乙免去年同期未实现批签发外，其余4个品种均有一定程度下滑。卫光生物仅白蛋白和纤原实现批签发。泰邦生物1月批签发白蛋白、静丙和破免3个品种，除静丙外，其余2个品种批签发量有所下滑。行业重大事件点评报告请务必阅读正文之后的免责条款部分3of4表1：部分上市公司1月份血制品批签发量汇总（单位：瓶）天坛生物华兰生物双林生物博雅生物上海莱士卫光生物泰邦生物人血白蛋白64472022223519091536382966584009556069增速143%-49%-33%151%-30%-69%-56%静注人免疫球蛋白427930391161118333794712674569874增速58%102%103%-50%-65%110%狂免144928100133增速-46%乙免143163101558增速46.6%破免14586014626712722062719增速-47%-56%人凝血因子(Ⅷ)158919762增速-82%人纤维蛋白原8473243709824增速60%凝血酶原复合物47588增速536%数据来源：中检院，国开证券研究部整体我们认为血制品行业在供需关系推动下，景气度有望持续改善，建议密切跟踪进口白蛋白批签发情况，建议逢低关注以天坛生物、华兰生物为代表的行业龙头。表2：相关重点个股估值情况（EPS单位：元/股；PE单位：倍；收盘价单位：元）证券代码证券简称EPSPEEPSPE收盘价(2020E)(2020E)(2021E)(2021E)20210218600161.SH天坛生物0.5377.790.6464.5741.26002007.SZ华兰生物0.8756.921.0547.2849.66数据来源：wind、国开证券研究部注：上述公司盈利预测来源于wind一致预期。风险提示：疫情影响超预期；行业监管政策进一步收紧；医保政策压力；行业事件性负面冲击；上市公司业绩增长低于预期；国内外经济形势持续恶化风险；国内外市场整体系统性风险。行业重大事件点评报告请务必阅读正文之后的免责条款部分4of4分析师简介承诺王雯，CFA、CPA，天津大学学士，对外经济贸易大学硕士研究生，曾任渤海证券医药行业分析师，8年行业研究经验。本人具有中国证券业协会授予的证券投资咨询执业资格并注册登记为证券分析师，保证报告所采用的数据均来自合规公开渠道，分析逻辑基于作者的专业与职业理解。本报告清晰准确地反映了作者的研究观点，力求独立、客观和公正，研究结论不受任何第三方的授意或影响，特此承诺。国开证券投资评级标准行业投资评级强于大市：相对沪深300指数涨幅10%以上；中性：相对沪深300指数涨幅介于-10%～10%之间；弱于大市：相对沪深300指数跌幅10%以上。短期股票投资评级强烈推荐：未来六个月内，相对沪深300指数涨幅20%以上；推荐：未来六个月内，相对沪深300指数涨幅介于10%～20%之间；中性：未来六个月内，相对沪深300指数涨幅介于-10%～10%之间；回避：未来六个月内，相对沪深300指数跌幅10%以上。长期股票投资评级A：未来三年内，相对于沪深300指数涨幅在20%以上；B：未来三年内，相对于沪深300指数涨跌幅在20%以内；C：未来三年内，相对于沪深300指数跌幅在20%以上。免责声明国开证券股份有限公司经中国证券监督管理委员会核准，具有证券投资咨询业务资格。本报告仅供国开证券股份有限公司（以下简称“本公司”）的客户使用。本公司不会因接收人收到本报告而视其为客户。本报告信息均来源于公开资料，本公司对这些信息的准确性和完整性不作任何保证。本报告所载的资料、意见及推测仅反映本公司于发布本报告当日的判断。在不同时期，本公司可发出与本报告所载资料、意见及推测不一致的报告。报告中的内容和意见仅供参考，并不构成对所述证券买卖的出价或询价。本报告所载信息均为个人观点，并不构成所涉及证券的个人投资建议，也未考虑到个别客户特殊的投资目标、财务状况或需求。客户应考虑本报告中的任何意见或建议是否符合其特定状况。本文中提及的投资价格和价值以及这些投资带来的收入可能会波动。本公司及分析师均不会承担因使用报告而产生的任何法律责任。客户（投资者）必须自主决策并自行承担投资风险。本报告版权仅为本公司所有，本公司对本报告保留一切权利，未经书面许可，任何机构和个人不得以任何形式翻版、复制、发表或引用本报告的任何部分。如征得本公司同意进行引用、刊发的，需在允许的范围内使用，并注明出处为“国开证券”，且不得对本报告进行任何有悖原意的引用、删节和修改。国开证券研究部地址：北京市阜成门外大街29号国家开发银行8层","data":[{"id":"1","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"1月，我国血制品实现批签发701.7万瓶","content_offset":["212","232"],"indicators":[{"indicator_name":"批签发量","indicator_value":["701.7万瓶","225","232"],"indicator_element":{"时间":["1月","212","214"],"行业":["血制品","217","220"],"区域":["我国","215","217"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"同比下滑7.2%","content_offset":["233","241"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑7.2%","235","241"],"indicator_element":{"时间":["1月","195","197"],"行业":["血制品","197","200"],"区域":["我国","215","217"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"环比下滑30.96%","content_offset":["242","252"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["下滑30.96%","244","252"],"indicator_element":{"时间":["1月","195","197"],"行业":["血制品","197","200"],"区域":["我国","215","217"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"1月，人血白蛋白批签发433.8万瓶","content_offset":["294","312"],"indicators":[{"indicator_name":"批签发量","indicator_value":["433.8万瓶","305","312"],"indicator_element":{"时间":["1月","294","296"],"行业":["血制品","197","200"],"产品":["人血白蛋白","297","302"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"同比下滑1%","content_offset":["313","319"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑1%","315","319"],"indicator_element":{"时间":["1月","294","296"],"行业":["血制品","217","220"],"产品":["人血白蛋白","297","302"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"其中进口白蛋白批签发261.5万瓶（-14.9%）","content_offset":["320","345"],"indicators":[{"indicator_name":"批签发量","indicator_value":["261.5万瓶（-14.9）","-1","-1"],"indicator_element":{"时间":["1月","294","296"],"行业":["血制品","955","958"],"产品":["进口白蛋白","322","327"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"国产白蛋白批签发172.3万瓶（+33.7%）","content_offset":["346","369"],"indicators":[{"indicator_name":"批签发量","indicator_value":["172.3万瓶（+33.7%）","354","369"],"indicator_element":{"时间":["1月","294","296"],"行业":["血制品","955","958"],"产品":["国产白蛋白","346","351"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"进口白蛋白占比60.27%","content_offset":["370","383"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["60.27%","377","383"],"indicator_element":{"时间":["1月","294","296"],"行业":["血制品","955","958"],"产品":["进口白蛋白","370","375"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"国产白蛋白占比39.73%","content_offset":["384","397"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["39.73%","391","397"],"indicator_element":{"时间":["1月","294","296"],"行业":["血制品","955","958"],"产品":["国产白蛋白","384","389"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"静丙方面，1月份共批签发静丙104.8万瓶","content_offset":["517","538"],"indicators":[{"indicator_name":"批签发量","indicator_value":["104.8万瓶","531","538"],"indicator_element":{"时间":["1月","522","524"],"行业":["血制品","955","958"],"产品":["静丙","517","519"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"同比下滑-13%","content_offset":["539","547"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑-13%","541","547"],"indicator_element":{"时间":["1月","522","524"],"行业":["血制品","955","958"],"产品":["静丙","517","519"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"狂免、破免及乙免分别批签发40.8万瓶（-47%）、64.9万瓶（+70%）及24.5万瓶（+151%）","content_offset":["577","629"],"indicators":[{"indicator_name":"批签发量","indicator_value":["40.8万瓶（-47%）","590","602"],"indicator_element":{"产品":["狂免","577","579"],"时间":["1月","522","524"],"行业":["血制品","955","958"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["64.9万瓶（+70%）","603","615"],"indicator_element":{"产品":["破免","580","582"],"时间":["1月","522","524"],"行业":["血制品","955","958"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["24.5万瓶（+151%）","616","629"],"indicator_element":{"产品":["乙免","583","585"],"时间":["1月","522","524"],"行业":["血制品","955","958"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"人凝血因子(Ⅷ)、纤原及人凝血酶原复合物分别批签发7.03万瓶（-79%）、10.2万瓶（42%）和4.76万瓶（-24%）","content_offset":["638","700"],"indicators":[{"indicator_name":"批签发量","indicator_value":["7.03万瓶（-79%）","663","675"],"indicator_element":{"产品":["人凝血因子(Ⅷ)","638","646"],"时间":["1月","711","713"],"行业":["血制品","955","958"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["10.2万瓶（42%）","676","687"],"indicator_element":{"产品":["纤原","647","649"],"时间":["1月","711","713"],"行业":["血制品","955","958"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["4.76万瓶（-24%）","688","700"],"indicator_element":{"产品":["人凝血酶原复合物","650","658"],"时间":["1月","711","713"],"行业":["血制品","955","958"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"2021年1月，我国血制品实现批签发701.7万瓶","content_offset":["1181","1206"],"indicators":[{"indicator_name":"批签发量","indicator_value":["701.7万瓶","1199","1206"],"indicator_element":{"时间":["2021年1月","1181","1188"],"行业":["血制品","1191","1194"],"区域":["我国","1189","1191"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"同比下滑7.2%","content_offset":["233","241"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑7.2%","235","241"],"indicator_element":{"时间":["1月","195","197"],"行业":["血制品","197","200"],"区域":["我国","215","217"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"环比下滑30.96%","content_offset":["242","252"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["下滑30.96%","244","252"],"indicator_element":{"时间":["1月","195","197"],"行业":["血制品","197","200"],"区域":["我国","215","217"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"人血白蛋白1月份批签发433.8万瓶（统一折算为10g规格）","content_offset":["1273","1303"],"indicators":[{"indicator_name":"批签发量","indicator_value":["433.8万瓶","1284","1291"],"indicator_element":{"时间":["1月","1278","1280"],"行业":["血制品","1191","1194"],"产品":["人血白蛋白","1273","1278"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"同比下滑1%","content_offset":["313","319"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑1%","315","319"],"indicator_element":{"时间":["1月","294","296"],"行业":["血制品","217","220"],"产品":["人血白蛋白","297","302"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"其中进口白蛋白批签发261.5万瓶（-14.9%）","content_offset":["320","345"],"indicators":[{"indicator_name":"批签发量","indicator_value":["261.5万瓶（-14.9）","-1","-1"],"indicator_element":{"时间":["1月","294","296"],"行业":["血制品","955","958"],"产品":["进口白蛋白","322","327"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"国产白蛋白批签发172.3万瓶（+33.7%）","content_offset":["346","369"],"indicators":[{"indicator_name":"批签发量","indicator_value":["172.3万瓶（+33.7%）","354","369"],"indicator_element":{"时间":["1月","294","296"],"行业":["血制品","955","958"],"产品":["国产白蛋白","346","351"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"进口白蛋白占比60.27%","content_offset":["370","383"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["60.27%","377","383"],"indicator_element":{"时间":["1月","294","296"],"行业":["血制品","955","958"],"产品":["进口白蛋白","370","375"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"国产白蛋白占比39.73%","content_offset":["384","397"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["39.73%","391","397"],"indicator_element":{"时间":["1月","294","296"],"行业":["血制品","955","958"],"产品":["国产白蛋白","384","389"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"1月份共批签发静丙104.8万瓶（含冻干，统一折算为2.5g规格）","content_offset":["1513","1546"],"indicators":[{"indicator_name":"批签发量","indicator_value":["104.8万瓶","1522","1529"],"indicator_element":{"时间":["1月","1513","1515"],"行业":["血制品","2214","2217"],"产品":["静丙","1520","1522"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"同比下滑-13%","content_offset":["539","547"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑-13%","541","547"],"indicator_element":{"时间":["1月","522","524"],"行业":["血制品","955","958"],"产品":["静丙","517","519"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"同比增长58%","content_offset":["1580","1587"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["58%","1584","1587"],"indicator_element":{"时间":["1月","1513","1515"],"行业":["血制品","2214","2217"],"产品":["天坛生物","1558","1562"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"狂免、破免及乙免分别批签发40.8万瓶（-47%）、64.9万瓶（+70%）及24.5万瓶（+151%）","content_offset":["577","629"],"indicators":[{"indicator_name":"批签发量","indicator_value":["40.8万瓶（-47%）","590","602"],"indicator_element":{"产品":["狂免","577","579"],"时间":["1月","522","524"],"行业":["血制品","955","958"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["64.9万瓶（+70%）","603","615"],"indicator_element":{"产品":["破免","580","582"],"时间":["1月","522","524"],"行业":["血制品","955","958"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["24.5万瓶（+151%）","616","629"],"indicator_element":{"产品":["乙免","583","585"],"时间":["1月","522","524"],"行业":["血制品","955","958"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"医药行业点评报告：1月血制品行业批签发数据点评.pdf","content":"人凝血因子(Ⅷ)、纤原及人凝血酶原复合物分别批签发7.03万瓶（-79%）、10.2万瓶（42%）和4.76万瓶（-24%）","content_offset":["638","700"],"indicators":[{"indicator_name":"批签发量","indicator_value":["7.03万瓶（-79%）","663","675"],"indicator_element":{"产品":["人凝血因子(Ⅷ)","638","646"],"时间":["1月","711","713"],"行业":["血制品","955","958"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["10.2万瓶（42%）","676","687"],"indicator_element":{"产品":["纤原","647","649"],"时间":["1月","711","713"],"行业":["血制品","955","958"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["4.76万瓶（-24%）","688","700"],"indicator_element":{"产品":["人凝血酶原复合物","650","658"],"时间":["1月","711","713"],"行业":["血制品","955","958"]},"indicator_supplement":{"属性":""}}]}]}